This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Author Affiliations
- Department of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa
- Corresponding Author: Jesse R. Richards, DO, Schusterman Center, Office 3J33, 4502 E 41st St, Tulsa, OK 74135 ([email protected]).
- Department of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa
- College of Medicine, University of Oklahoma School of Community Medicine, Tulsa
- College of Medicine, University of Oklahoma School of Community Medicine, Tulsa
- College of Medicine, University of Oklahoma School of Community Medicine, Tulsa
- Department of Pharmacology & Physiology, Oklahoma State University, Center for Health Sciences, Tulsa
- Oklahoma State University Biomedical Imaging Center, OSU-Center for Health Sciences, Tulsa
References (18)
- Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043. PubMed CrossRef
- Han B, Jones CM, Einstein EB, et al. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021;78(8):922–924. PubMed CrossRef
- Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023;14:1063033. PubMed CrossRef
- Chuong V, Farokhnia M, Khom S, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671. PubMed CrossRef
- Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642. PubMed CrossRef
- Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. PubMed CrossRef
- Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124. PubMed CrossRef
- Rubino DM, Greenway FL, Khalid U, et al; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–150. PubMed CrossRef
- Thomsen M, Holst JJ, Molander A, et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology (Berl). 2019;236(2):603–611. PubMed CrossRef
- Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, et al. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events: a nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol. 2022;131(5):372–379. PubMed CrossRef
- Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6(8):148. PubMed CrossRef
- Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804. PubMed CrossRef
- Conigrave KM, Hall WD, Saunders JB. The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. Addiction. 1995;90(10):1349–1356. PubMed CrossRef
- Babor TF, Higgins-Biddle J, Saunders JB, et al. World Health Organization. AUDIT-The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Heath Care. Second Edition. 2001:1–40.
- Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry. 2010;71(5):634–648. PubMed CrossRef
- Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86–90. PubMed CrossRef
- Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016;387(10022):988–998. PubMed CrossRef
- Marty VN, Farokhnia M, Munier JJ, et al. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci. 2020;14:599646. PubMed CrossRef
